Page last updated: 2024-09-05

orantinib and Hypoxia

orantinib has been researched along with Hypoxia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Erber, R; Groth, G; Hammes, HP; Katsen, AD; Kerger, H; Menger, MD; Thurnher, A; Ullrich, A; Vajkoczy, P	1

Other Studies

1 other study(ies) available for orantinib and Hypoxia

Article	Year
Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, Volume: 18, Issue:2 Topics: Animals; Apoptosis; Cell Survival; Hypoxia; Indoles; Microcirculation; Models, Biological; Neoplasms; Neovascularization, Pathologic; Oxindoles; Pericytes; Platelet-Derived Growth Factor; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2004

Article

Year

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, Volume: 18, Issue:2

Topics: Animals; Apoptosis; Cell Survival; Hypoxia; Indoles; Microcirculation; Models, Biological; Neoplasms; Neovascularization, Pathologic; Oxindoles; Pericytes; Platelet-Derived Growth Factor; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2004